Anders Månsson recently visited BioStock Studio to talk about his new role as CEO of Oncoinvent, a privately held company headquartered in Oslo. The company’s lead candidate is Radspherin, an alpha-radiating radiopharmaceutical developed for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer. During the interview, Månsson described Radspherin’s mechanism of action and the company’s clinical development plans for the candidate. Furthermore, he shed light on radiopharmaceuticals as an emerging hot spot in oncology attracting great interest from both big pharma and institutional investors.
Watch the interview with Oncoinvent’s CEO Anders Månsson below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.